Braveheart Bio (BRVE) stock

Cardiovascular therapeutics , market cap $1.9B

Therapeutics for cardiovascular diseases

Market cap $1.9B

$21.87

+2.01%

As of Monday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#76of 291

Biotech

Checks firing

6of 14

Trending down

From its high

-31.7%

No 200-day yet

BRVE's Quality Score rose 4 points on Mon, Oct 26, to 5. Closed above its rising 21-day average (3 chart checks started). 1 more reason, for Pro members.

New listing, trading since Aug 6, 2026. 57 trading days so far, so 4 of the 14 chart checks wait for more history.

Follow BRVE's trial news. Pro members can get an alert when Braveheart Bio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when BRVE files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“…Phase 3 study in obstructive HCM (“oHCM”), and we are on track to dose the first patient this year…”Trial start · SEC filing · Sep 8

Key facts on BRVE

Key facts on BRVE
Holding it back	165.1% more shares than a year ago
Latest filing	10-Q, Sep 8 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

2 more reasons behind BRVE's 5, for Pro members.

BRVE catalysts

Coming up

After its last report it closed -1.7%.

1 more coming up and 1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for BRVE, and how long its cash lasts

Next step the company has named

2026“Sites are being activated and patients are screening for our LIONHEART-HCM Phase 3 study in obstructive HCM (“oHCM”), and we are on track to dose the first patient this year.”Trial start · SEC filing · Sep 8

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: LIONHEART-HCMPhase 3 · Recruiting · 210 people · main data estimated Oct 2028 · NCT07755904

For Pro members: 1 more milestone and 2 filings.

Cash runway Jun 30 balance sheet

$123M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Sep 8). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Erez Chimovits bought 1,940,000 shares on Aug 7. 7 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Travis Murdoch buys or sells

For Pro members: every trade, and Travis Murdoch’s 3 filings and quotes.

Get an alert when BRVE files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Why BRVE scores 5

Below AverageTrending down, 6 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. BRVE scores 5 today, against a median of 1 over its last 20 recorded sessions.

+6Chart checks 6 of 14 firing right now, one point each
−2Dilution 165.1% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Insider trades adds

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Cash flow, Persistence, and News.

What every line is worth, and the reason behind it, on BRVE and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 9:21 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when BRVE's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on BRVE and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

BRVE has 6 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on BRVE, and all 14 on every stock.Get in free →

BRVE RSI today: 51.5, below its 50-day average

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1451.5
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 7 sessions ago.
50-day average$24.01
The price is 8.9% below it.
200-day average
Not enough history yet.
50/200 cross
Not enough history yet.
ADX 1428.2
25 or more, with +DI below -DI.
Support$18.00
Swing low from Oct 16, 17.7% below the price.
Resistance$29.50
Swing high from Sep 18, 34.9% above the price.
High since listing$32.00
From Aug 7, 46.3% above the price.
Low since listing$17.86
From Oct 8, 18.3% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $18.14 to $22.53.
Volume0.2x
Against its 20-day average, for the time of day.

The deep dive on BRVE

What it does and how it makes money1 findingFor Pro members1 finding on what BRVE does and how it makes money, for Pro members
Where it stands1 findingFor Pro members1 finding on where BRVE stands: its cash, debt, and share count, for Pro members
Who holds and trades it3 findingsInsiders bought $89.2M of shares on the open market in 90 days, with no sales; the largest, 10% owner Forbion Growth Opportunities Fund III Cooperatief U.A., bought $34.6M on Aug 7, 2026.Form 4, filed Aug 7, 2026

4 more findings on BRVE, each with its source, for Pro membersGet in free →

How BRVE ranks in Biotech

BRVE is #76 of 291 by Quality Score.

How BRVE ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	AMRXAmneal Pharmaceuticals	9/14	20
3	RIGLRigel Pharmaceuticals	9/14	19
	BMRNBioMarin Pharmaceuticals		Open for its score
	BNTXBioNTech		Open for its score
	CABACabaletta Bio		Open for its score
	CADLCandel Therapeutics		Open for its score
76	BRVEBraveheart Bio	6/14	5

When does BRVE report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 17 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What BRVE reported on Sep 8, 2026

The quarter

The figures are not read from the release yet.

“The increase was primarily due to the advancement of BHB-1893, preparation for the planned global Phase 3 program, and higher personnel-related costs.”

The filing on EDGAR

Where the sales came from

BRVE's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“Based on the current operating plan, Braveheart Bio estimates that its existing cash and cash equivalents, together with the net proceeds from its IPO, will be sufficient to fund its projected operating expenses and capital expenditure requirements into 2029.”

From its results filing (SEC filing · Sep 8)

2 more sentences, for Pro members.

The numbers

Market value: $1.9B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on BRVE: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

-1.7%

Sep 8

Reported	When	Gap	Reaction	5 sessions
Sep 8, 2026After close	After close	-0.9%	-1.7%	-9.2%

BRVE closed higher after 0 of its last 1 report.

BRVE share count over time

Shares: 2.7 times the count a year ago (to Jun 30).

Shares of BRVE outstanding, as filed
Shares outstanding	As of
90M	Sep 3, 2026

Offerings, shelves, and splits of BRVE, from its filings
From its filings	Filed
Raised $382.5M in a sale of shares, about 20% of its market value	Aug 6, 2026
Registered shares for sale (S-1)	Jul 15, 2026

Who is trading BRVE

BRVE insider trades

8 insiders bought $89.2M across 9 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyAH BIO Fund IV, L.P.$19.8M10% ownerat $18.00 on Aug 7, filed Aug 11

BuyAH BIO Fund IV, L.P.10% owner$19.8Mat $18.00 on Aug 7, filed Aug 11

All 9 insider filings on BRVE from the last six months, for Pro members.Get in free →

All BRVE insider trades

BRVE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Travis MurdochCEO and President · 1 trade
James Paul RickeyChief Financial Officer · 1 trade
Michele A. AndersonChief Development Officer · 1 trade
Christopher ViehbacherDirector · 1 trade
David Charles LubnerDirector · 1 trade
David I. MalekDirector · 1 trade

See insider trades by person

About Braveheart Bio

Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).

San Francisco, CAbraveheart.bio

Listed on Nasdaq on Aug 6, 2026, and is 22% above its $18 offer price now. Its IPO filing and first days

BRVE's score card

Braveheart Bio (BRVE): Quality Score 5, Below Average, #76 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn BRVE's score around: 4 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayAug 11AH BIO Fund IV, L.P. bought BRVE$19.8M at $18.00, filed Aug 11

Alerts are optional.

See BRVE's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: BRVE's Quality Score is 5 (Below Average), #76 of 291 in Biotech. Insiders bought $89.2M in the last 6 months (Form 4).

Is BRVE a good stock to buy? What its Quality Score says

BRVE scores 5 today, which Breakaway calls Below Average. It is #76 of 291 in Biotech by Quality Score, with 6 of 14 chart checks firing. Shares: 2.7 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is BRVE's Quality Score?

BRVE scores 5 today, which Breakaway calls Below Average (0 to 5). That is #76 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BRVE's 5.

Are insiders buying BRVE?

8 insiders bought $89.2M across 9 filings in the last 6 months. No open-⁠market sales on record. The newest is AH BIO Fund IV, L.P., 10% owner, who bought $19.8M on Aug 7. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.